Boston Scientific has introduced the Promus Element Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan.

The Promus Element Stent utilizes a proprietary PtCr alloy which is designed specifically for coronary stenting, which enables enhanced visibility, less recoil, excellent conformability and higher radial strength.

The Stent also includes an advanced low-profile delivery system designed to provide physicians improved drug-eluting stent performance in treating patients with coronary artery disease.

Boston Scientific chief executive officer Hank Kucheman said this approval marks two important milestones for the company.

"First, the Promus Element Stent platform is now approved in every major market worldwide," Kucheman added.

"Second, we have begun the last phase of our transition to higher margins on our everolimus stent offering as we shift to the internally manufactured Promus Element Stent."